What is it about?
In Stargardt disease type 1, photoreceptors have long been considered passive victims of damage. Our study shows that photoreceptors make an autonomous contribution to STGD1 pathogenesis, expanding our understanding of the mechanisms driving disease progression. It also highlights mitochondrial modulation as a potential therapeutic strategy, opening new avenues for the treatment of this disease.
Featured Image
Photo by Swapnil Potdar on Unsplash
Why is it important?
Our study demonstrates that photoreceptors autonomously contribute to STGD1 pathogenesis, broadening our understanding of the mechanisms underlying disease progression. Moreover, it identifies mitochondrial modulation as a promising therapeutic strategy, opening new avenues for treatment.
Perspectives
Our study positions mitochondrial dysfunction as a key driver of STGD1 pathology and highlights miR-181a/b downregulation as a promising therapeutic avenue.
Alessia Indrieri
Telethon Institute of Genetics and Medicine
Read the Original
This page is a summary of: Uncovering mitochondrial defects in photoreceptors opens therapeutic opportunities for Stargardt disease, Proceedings of the National Academy of Sciences, April 2026, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2504764123.
You can read the full text:
Contributors
The following have contributed to this page
